International Journal of Endocrinology / 2017 / Article / Tab 1

Research Article

Therapeutic Outcomes of Patients with Multifocal Papillary Thyroid Microcarcinomas and Larger Tumors

Table 1

Clinical features of multifocal or solitary papillary thyroid cancer.

Clinical characteristicsAll patientsMultifocalSolitary value

Patient number2536 (100.0)626 (24.7)1910 (75.3)
Gender, female1996 (78.7)499 (79.7)1497 (78.4)0.479
Age at diagnosis (year)43.7 ± 14.046.5 ± 13.542.7 ± 14.0<0.001
1174 (46.3)355 (56.7)819 (42.9)<0.001
Mean tumor size (cm)2.3 ± 1.62.1 ± 1.42.3 ± 1.60.003
1-month postoperative serum Tg level (ng/mL)157.4 ± 1851.2184.2 ± 1551.1148.6 ± 1939.70.683
Variants
 Hashimoto (lymphocytic) thyroiditis133 (5.2)29 (4.6)104 (5.4)0.429
 Follicular variant of PTC382 (15.1)99 (15.8)293 (15.3)0.776
 Poorly differentiated + tall cell36 (1.4)8 (1.3)28 (1.5)0.730
Operative method
 Total thyroidectomy2191 (86.4)595 (95.0)1596 (83.6)<0.001
TNM stage
 Stage I1772 (69.9)390 (62.3)1382 (72.4)<0.001
 Stages II–IV764 (30.1)236 (37.7)528 (27.6)
Nonremission381 (15.0)131 (20.9)250 (13.1)<0.001
Follow-up period (year)9.4 ± 6.87.1 ± 5.310.2 ± 7.0<0.001
Postoperative 131I accumulative dose (mCi)130.6 ± 199.9153.7 ± 222.2123.0 ± 191.40.001
Radiation therapy114 (4.5)28 (4.5)86 (4.5)0.975
2nd primary cancer180 (7.1)49 (7.8)131 (6.9)0.413
Diabetes mellitus210 (8.3)61 (9.7)149 (7.8)0.126
Overall mortality227 (9.0)49 (7.8)178 (9.3)0.256
Cancer mortality109 (4.3)25 (4.0)84 (4.4)0.665
Disease-free982 (38.7)221 (35.3)761 (39.8)0.043
Lymph node metastasis581 (22.9)197 (31.5)384 (20.1)<0.001
Soft tissue invasion520 (20.5)153 (24.4)367 (19.2)0.005
Distant metastasis112 (4.4)39 (6.2)73 (3.8)0.011

Number (%); mean ± SD.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.